Edition:
United Kingdom

Cytosorbents Corp (CTSO.OQ)

CTSO.OQ on NASDAQ Stock Exchange Capital Market

9.90USD
16 Nov 2018
Change (% chg)

$0.32 (+3.34%)
Prev Close
$9.58
Open
$9.50
Day's High
$9.93
Day's Low
$9.49
Volume
69,934
Avg. Vol
50,053
52-wk High
$14.90
52-wk Low
$5.80

Latest Key Developments (Source: Significant Developments)

Cytosorbents Awarded Up To $3 Mln In Funding
Tuesday, 21 Aug 2018 

Aug 21 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS AWARDED UP TO $3M IN SBIR PHASE IIB BRIDGE FUNDING BY NIH/NHLBI.  Full Article

Cytosorbents Files For Mixed Shelf Of Up To $150 Million
Thursday, 26 Jul 2018 

July 26 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING.  Full Article

Cytosorbents Sees Q4 2017 Revenue About $4.6 Million
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS PRE-ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND ISSUES STOCKHOLDER LETTER.SEES Q4 2017 REVENUE ABOUT $4.6 MILLION.SEES FY 2017 REVENUE $15 MILLION.- WITH NEW TAX LAW, AND WITH SUBSTANTIAL FEDERAL NET OPERATING LOSSES "WE WILL NOT PAY FEDERAL INCOME TAX FOR A LONG TIME".  Full Article

U.S. FDA Approves Cytosorbents' Refresh 2 IDE Application With Conditions
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS ACHIEVES KEY MILESTONE WITH FDA APPROVAL OF THE U.S. REFRESH 2 PIVOTAL CARDIAC SURGERY TRIAL IDE APPLICATION.U.S. FDA GRANTED APPROVAL OF REFRESH 2 INVESTIGATIONAL DEVICE EXEMPTION APPLICATION, WITH CONDITIONS.CONDITIONS RELATE TO REQUESTED CLARIFICATIONS, CHANGES TO PATIENT CONSENT FORM & INSTRUCTIONS FOR USE DOCUMENT.  Full Article

Cytosorbents posts Q3 revenue of $3.8 mln
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Cytosorbents Corp :Cytosorbents continues strong trajectory of growth in the third quarter 2017.Total Q3 2017 revenues increased 59% to $3.8 million​.  Full Article